HempNewsBreaks

FridaySep 27, 2024 3:20 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands. Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as…

Continue Reading

FridaySep 20, 2024 1:21 pm

HempNewsBreaks – Cannabis Conference and Expo Creates Key Opportunity for Cannabis Innovation to Meet Cannabis Community

Cannabis Conference and Expo: Grow Up 2024 will be held in Edmonton, Alberta, later this month. The three-day event is slated for Sept. 29–Oct. 1, 2024, and will bring together top growers, the largest cannabis brands and thousands of delegates for an invaluable conference and trade show designed to provide key information about relevant topics in the cannabis industry. The event is Canada’s largest conference and expo. The event agenda features an exclusive riverboat kick-off party, expo days, a Canadian cannabis championship, an array of addresses, panel presentations and workshops by industry experts and an insightful interview with legendary cannabis…

Continue Reading

FridaySep 13, 2024 3:30 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). “Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D expenditures and experienced other savings,” reads a recent article. “Most importantly, however, were the program updates for initiatives it embarked on for 2024. A highlight of its projects has been its glucagon-like peptide-1 (‘GLP-1’) agonist research program. GLP-1, a class of drugs, has demonstrated an…

Continue Reading

ThursdaySep 12, 2024 2:08 pm

HempNewsBreaks – CannabisNewsWire and IBN Partner with NY Cannabis Insider to Boost Visibility for Premier Cannabis Event

CannabisNewsWire (“CNW”), a specialized communications platform for the cannabis sector and one of the 65+ brands powered by IBN, on Thursday announced that it has been named the Official NewsWire of the NY Cannabis Insider event, with IBN serving as the Official Media Sponsor. The event, scheduled for September 25, 2024, at The Desmond Hotel in Albany, NY, will focus on "Making Money in the Legal NYS Market," featuring industry leaders sharing insights on building profitable cannabis businesses. CNW will amplify the event’s coverage through its vast syndication network, while IBN will drive visibility across its family of brands. This…

Continue Reading

ThursdaySep 12, 2024 12:05 pm

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Partnership to Boost Operational Capacity, Sustain Revenue Growth in Logistics Division

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced a strategic partnership between LE Logistics, LLC, its wholly owned subsidiary, and West End Trucking, Inc. The partnership is expected to significantly boost the company’s asset base and operational capacity and set the stage for continued revenue growth and long-term success. Under the partnership, LE Logistics will manage and operate a fleet of 13 trucks and trailers under its own and West End’s licenses. Specifically, LE Logistics will handle all day-to-day logistics operations and create a robust system for fleet management, while West End will ensure compliance with all…

Continue Reading

ThursdaySep 05, 2024 11:16 am

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a recognized industry veteran with over three decades of experience in the medical device and pharmaceutical industries. He has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. Mr. Christopher takes over from outgoing CEO, Chris Bunka, who has stepped aside from the role. Mr. Bunka remains as the Chairman of the Board of Directors and has been appointed Executive Strategic Advisor to the…

Continue Reading

TuesdaySep 03, 2024 12:24 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has entered into a Materials Transfer Agreement with a pharmaceutical company. Under the terms of the agreement, the pharmaceutical company will evaluate Lexaria’s DehydraTECH(TM) technology in a pre-clinical setting. Lexaria will be responsible for formulating and supplying certain DehydraTECH compositions, with the pharmaceutical company evaluating the pharmacokinetics of these compositions in animal studies. According to the company, Lexaria has awarded the pharmaceutical company a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work is expected to be completed within roughly 6 months…

Continue Reading

FridayAug 30, 2024 2:45 pm

HempNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth

InMed Pharmaceuticals’ (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth. The company published a report on the expansion of the minor cannabinoid market in 2023. “The report, based on data from Headset, the largest industry dataset, explores the growth, competition and consumer trends in ten regulated states, encompassing 85 million of the 158 million residents in areas where recreational cannabis is legal,” reads a recent article. “The report highlights a 5.4% revenue increase in the edible market,…

Continue Reading

FridayAug 30, 2024 1:25 pm

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Makes ‘Transformative Step’ in Vision to Build Diverse Portfolio

Golden Triangle Ventures (OTC: GTVH) previously announced a full-service freight brokerage business designed to significantly expand its logistics capabilities in a strategic move that aligns with its vision to assemble a strong portfolio. “The announcement comes as the company completed its acquisition of Cargo Management Group from T&K Zarro LLC and received the full financial commitment needed to launch the freight brokerage business. The Cargo Management Group acquisition includes a full-fledged logistics operation, brokerage business, licenses, and all associated assets… Golden Triangle Ventures also noted that, along with the acquisition, the company received full financial support from T&K Zarro to…

Continue Reading

ThursdayAug 29, 2024 12:13 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the tolerability and additional pharmacokinetic (“PK”) results from its human pilot study #2, GLP-1-H24-2, have been received. According to the results, absorption improvements appear to continue with DehydraTECH-processed Rybelsus(R) vs. Rybelsus tablets, even under “fed” conditions. The results also show that DehydraTECH-treated Rybelsus does absorb through a mouth-melt product format. “We were pleased to find that none of the nine people taking the DehydraTECH-processed Rybelsus swallowed as a capsule experienced any adverse events whatsoever,” the company stated in the press release. “However, of the nine human…

Continue Reading